The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis

McAllister SD and Glass M (2002) CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids 66: 161–171

Mechoulam R, Panikashvili D and Shohami E (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8: 58–61

Di Marzo V (1998) ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta 1392: 153–175

Maccarrone M and Finazzi-Agrò A (2002) Endocannabinoids and their actions. Vitam. Horm. 65: 225–255

Pertwee RG (2001) Cannabinoid receptors and pain. Prog. Neurobiol. 63: 569–611

Sugiura T, Kobayashi Y, Oka S and Waku K (2002) Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot. Essent. Fatty Acids 66: 173–192

Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I and Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 98: 3662–3665

MacDonald JC and Vaughan CW (2001) Cannabinoids act backwards. Nature 410: 527–530

Wilson RI and Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296: 678–682

Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S and Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 99: 10819–10824

Hansen HH, Hansen SH, Schousboe A and Hansen HS (2000) Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azide-induced toxicity in cultured neocortical neurons. J. Neurochem. 75: 861–871

Hillard CJ and Jarrahian A (2000) The movement of N-arachidonoyl-ethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids 108: 123–134

Maccarrone M, Bari M, Battista N and Finazzi-Agrò A (2002) Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood 100: 4040–4048

Bracey MH, Hanson MA, Masuda KR, Stevens RC and Cravatt BF (2002) Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298: 1793–1796

Ueda N, Puffenbarger RA, Yamamoto S and Deutsch DG (2000) The fatty acid amide hydrolase (FAAH). Chem. Phys. Lipids 108: 107–121

Deutsch DG, Glaser ST, Howell JM, Kunz JS, Puffenbarger RA, Hillard CJ and Abumrad N (2001) The cellular uptake of anandamide is coupled to its breakdown by fatty acid amide hydrolase (FAAH). J. Biol. Chem. 276: 6967–6973

Day TA, Rakhshan F, Deutsch DG and Barker EL (2001) Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol. 59: 1369–1375

Van der Stelt M, van Kuik JA, Bari M, van Zadelhoff G, Leeflang BR, Veldink GA, Finazzi Agrò A, Vliegenthart JFG and Maccarrone M (2002) Oxygenated metabolites of anandamide and 2-arachidonoyl-glycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter and fatty acid amide hydrolase. J. Med. Chem. 45: 3709–3720

Mukhopadhyay S and Howlett AC (2001) CB1 receptor-G protein association Subtype selectivity is determined by distinct intracellular domains. Eur. J. Biochem. 268: 499–505

Reggio PH and Traore H (2000) Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem. Phys. Lipids 108: 15–35

Khanolkar AD, Palmer SL and Makriyannis A (2000) Molecular probes for the cannabinoid receptors. Chem. Phys. Lipids 108: 37–52

Jordt SE and Julius D (2002) Molecular basis for species-specific sensitivity to ‘hot’ chili peppers. Cell 108: 421–430

Di Marzo V, Bisogno T and De Petrocellis L (2001) Anandamide: some like it hot. Trends Pharmacol. Sci. 22: 346–349

De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agrò A and Di Marzo V (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276: 12856–12863

De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M and Di Marzo V (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. USA 95: 8375–8380

Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M and Di Marzo V (1999) Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. 463: 235–240

Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M and Di Marzo V (2000) Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141: 118–126

Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L and Di Marzo V (2001) Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 15: 2745–2747

Derocq J-M, Bouaboula M, Marchand J, Rinaldi-Carmona M, Ségui M and Casellas P (1998) The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett. 425: 419–425

Schwarz H, Blanco FJ and Lotz M (1994) Anandamide, an endogenous cannabinoid receptor agonist, inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55: 107–115

Sarker KP, Obara S, Nakata M, Kitajima I and Maruyama I (2000) Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. 472: 39–44

Galve-Roperh I, Sànchez C, Cortes ML, Gómez del Pulgar T, Izquierdo M and Guzman M (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6: 313–316

Sànchez C, Galve-Roperh I, Canova C, Brachet P and Guzman M (1998) Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436: 6–10

Chan GC-K, Hinds TR, Impey S and Storm DR (1998) Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. J. Neurosci. 18: 5322–5332

Ruiz L, Miguel A and Diaz-Laviada I (1999) Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. 458: 400–404

Sànchez C, de Ceballos ML, Gómez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramon y Cajal S and Guzman M (2001) Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res. 61: 5784–5789

Sànchez C, Rueda D, Segui B, Galve-Roperh I, Levade T and Guzman M (2001) The CB1 cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein FAN. Mol. Pharmacol. 59: 955–959

Rueda D, Galve-Roperh I, Haro A and Guzman M (2000) The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol. 58: 814–820

Gómez del Pulgar T, Velasco G, Sanchez C, Haro A and Guzman M (2002) De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J. 363: 183–188

Gómez del Pulgar T, Velasco G and Guzman M (2000) The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J. 347: 369–373

Gómez del Pulgar T, De Ceballos ML, Guzman M and Velasco G (2002) Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 277: 36527–36533

Galve-Roperh I, Rueda D, Gomez del Pulgar T, Velasco G and Guzman M (2002) Mechanism of extracellular signal-regulated kinase activation by the CB1 cannabinoid receptor. Mol. Pharmacol. 62: 1385–1392

Maccarrone M, Lorenzon T, Bari M, Melino G and Finazzi-Agrò A (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275: 31938–31945

Wahl GM and Carr AM (2001) The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat. Cell Biol. 3: 277–286

Esposito G, Ligresti A, Izzo AA, Bisogno T, Ruvo M, Di Rosa M, Di Marzo V and Iuvone T (2002) The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation. J. Biol. Chem. 277: 50348–50354

Jacobsson SO, Wallin T and Fowler CJ (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 299: 951–959

Maccarrone M, Cecconi S, Rossi G, Battista N, Pauselli R and Finazzi-Agrò A (2003) Anandamide activity and degradation are regulated by early postnatal ageing and follicle-stimulating hormone in mouse Sertoli cells. Endocrinology 144: 20–28

Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL and Guzman M (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111: 43–50

Maccarrone M, Pauselli R, Di Rienzo M and Finazzi-Agrò A (2002) Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem. J. 366: 137–144

Casaccia-Bonnefil P, Kong H and Chao MV (1999) Neurotrophins: the biological paradox of survival factors eliciting apoptosis. Cell Death Differ. 5: 357–364

Fernandez-Ruiz J, Berrendero F, Hernandez ML and Ramos JA (2000) The endogenous cannabinoid system and brain development. Trends Neurosci. 23: 14–20

Rueda D, Navarro B, Martinez-Serrano A, Guzman M and Galve-Roperh I (2002) The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J. Biol. Chem. 277: 46645–46650

Williams EJ, Walsh FS and Doherty P (2003) The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J. Cell Biol. 160: 481–486

Bifulco M and Di Marzo V (2002) Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat. Med. 8: 547–550

McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS and Nagarkatti M (2002) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100: 627–634